Circio Holding ASA: Mandatory notification of trade by primary insiders pertaining to settlement of RSUs

Summary by AI ^BETAClose X

Circio Holding ASA is increasing its share capital by NOK 70,516.20 through the issuance of 117,527 new shares, each with a nominal value of NOK 0.6, to facilitate the settlement of 52,027 restricted stock units (RSUs) for employees and board members. Notably, board members Damian Marron, Diane Mellett, and Thomas Falck have settled RSUs and subscribed for new shares at NOK 0.60 per share, with Thomas Falck selling 4,041 shares to cover tax obligations and exercise price. Following these transactions, Damian Marron holds 311,863 shares, Diane Mellett holds 262,258 shares and 12,670 RSUs, and Thomas Falck holds 415,535 shares.

Disclaimer*

Oslo, 7 May 2026: Reference is made to Circio Holding ASA’s (OSE: CRNA) (the "Company") stock exchange announcement published on 6 May 2026, regarding the board of directors' resolution to increase the Company's share capital with NOK 70,516.20 by the issuance of 117,527 new shares, each with a nominal value of NOK 0.6, in order to issue new shares in the Company to facilitate an exercise of 65,500 share options and settlement of 52,027 restricted stock units (“RSUs“) pursuant to the Company's long-term incentive program for its employees and the Company's program for RSUs for the board members.

Primary insider, Damian Marron, chairman of the board of directors, has settled 14,012 RSUs under his RSU agreement and subscribed for 14,012 new shares in the Company following the exercise of RSUs. The subscription price for the RSUs was NOK 0.60 per new share.
Primary insider, Diane Mellett, member of the board of directors, has settled 2,020 RSUs under her RSU agreement and subscribed for 2,020 new shares in the Company following the exercise of RSUs. The subscription price for the RSUs was NOK 0.60 per new share.
Primary insider, Thomas Falck, member of the board of directors, has settled 10,376 RSUs under his RSU agreement and subscribed for 10,376 new shares in the Company following the exercise of RSUs. The subscription price for the RSUs was NOK 0.60 per new share. In order to cover tax obligations and payment of exercise price related to the settlement of RSUs, Thomas Falck has elected to sell 4,041 of his subscribed 10,376 shares.

No primary insiders exercised any share options.

Following the RSU settlement and subscription of new shares and the registration of the share capital increase pertaining to the new shares with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret), the above-mentioned primary insiders hold the following:

Damian Marron holds 311,863 shares and no RSUs
Diane Mellett holds 262,258 shares and 12,670 RSUs
Thomas Falck holds 415,535 shares (including shares held through Sølen AS) and no RSUs

Please see the attached notifications of trade for information regarding the settlement of RSUs and sales of new shares, for the purpose of covering tax obligations and paying exercise price, by the primary insiders.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.